MeSH term
Frequency | Condition_Probility | Animals | 74 | 0.0 |
Humans | 143 | 0.0 |
Adult | 25 | 0.0 |
Aged | 6 | 0.0 |
Aged, 80 and over | 3 | 0.0 |
Alleles | 14 | 0.0 |
DNA/genetics | 2 | 0.0 |
Family Health | 2 | 0.0 |
Female | 30 | 0.0 |
Gene Frequency | 7 | 0.0 |
Genetic Predisposition to Disease/*genetics | 2 | 0.0 |
Genotype | 16 | 0.0 |
*Glycoproteins | 29 | 3.0 |
Male | 43 | 0.0 |
Middle Aged | 21 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 57 | 0.0 |
Risk Factors | 2 | 0.0 |
Apolipoproteins B/secretion | 4 | 50.0 |
Caco-2 Cells | 6 | 1.0 |
Carrier Proteins/*antagonists & inhibitors | 3 | 13.0 |
Dose-Response Relationship, Drug | 6 | 0.0 |
Liver/*metabolism | 7 | 1.0 |
Rats | 20 | 0.0 |
Research Support, Non-U.S. Gov't | 86 | 0.0 |
Tumor Cells, Cultured | 20 | 0.0 |
Carrier Proteins/*metabolism | 17 | 2.0 |
Lipids/*metabolism | 7 | 3.0 |
Lipoproteins/*biosynthesis | 3 | 23.0 |
Microsomes/*metabolism | 18 | 42.0 |
Particle Size | 2 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
Lipoproteins/*metabolism | 6 | 3.0 |
Protein Disulfide-Isomerase/metabolism | 4 | 50.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
Rabbits | 3 | 0.0 |
Rats, Sprague-Dawley | 4 | 0.0 |
Carrier Proteins/*pharmacology | 2 | 4.0 |
Enzyme-Linked Immunosorbent Assay | 4 | 0.0 |
Apolipoproteins B/blood | 3 | 1.0 |
Carrier Proteins/*genetics/metabolism | 4 | 1.0 |
Heterozygote | 6 | 0.0 |
Homozygote | 4 | 0.0 |
Lipids/blood | 5 | 0.0 |
Lipoproteins/*blood | 3 | 0.0 |
Microsomes/metabolism | 8 | 6.0 |
*Polymorphism, Genetic | 13 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Apolipoproteins B/*blood | 5 | 3.0 |
Carrier Proteins/*genetics | 27 | 2.0 |
Promoter Regions (Genetics)/*genetics | 4 | 0.0 |
Reference Values | 3 | 0.0 |
Triglycerides/blood | 9 | 0.0 |
Phenotype | 5 | 0.0 |
Severity of Illness Index | 2 | 0.0 |
Carcinoma, Hepatocellular | 7 | 2.0 |
Cholesterol/metabolism | 5 | 1.0 |
Liver/metabolism | 12 | 1.0 |
Liver Neoplasms | 4 | 1.0 |
RNA, Messenger/analysis | 5 | 0.0 |
Triglycerides/metabolism | 14 | 8.0 |
Tumor Cells, Cultured/drug effects/secretion | 2 | 16.0 |
Apolipoproteins B/blood/metabolism | 2 | 28.0 |
Disease Models, Animal | 3 | 0.0 |
Lipoproteins, VLDL/*secretion | 2 | 33.0 |
Mice | 20 | 0.0 |
Mice, Inbred C57BL | 6 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
Microscopy, Electron | 6 | 0.0 |
Triglycerides/blood/metabolism | 2 | 9.0 |
Cholesterol/*blood | 3 | 1.0 |
Cohort Studies | 3 | 0.0 |
Linkage Disequilibrium | 2 | 0.0 |
Lipoproteins, LDL/blood | 2 | 0.0 |
Mutation, Missense | 2 | 0.0 |
Point Mutation | 2 | 0.0 |
Promoter Regions (Genetics) | 5 | 0.0 |
Variation (Genetics) | 3 | 0.0 |
Anticholesteremic Agents/therapeutic use | 2 | 6.0 |
Apolipoproteins B/metabolism | 5 | 5.0 |
Clinical Trials | 3 | 0.0 |
Hyperlipidemia/*drug therapy | 3 | 10.0 |
Biological Transport | 5 | 0.0 |
Lipoproteins/biosynthesis | 2 | 14.0 |
Membrane Proteins/chemistry/genetics/*metabolism | 2 | 3.0 |
COS Cells | 7 | 0.0 |
Centrifugation, Density Gradient | 5 | 1.0 |
Comparative Study | 8 | 0.0 |
Hela Cells | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Transfection | 15 | 0.0 |
Apolipoproteins B/*metabolism | 10 | 10.0 |
Cell Line | 20 | 0.0 |
Methaqualone/analogs & derivatives/pharmacology | 2 | 100.0 |
Protein Biosynthesis | 2 | 0.0 |
Triazenes/pharmacology | 2 | 33.0 |
Triglycerides/biosynthesis/*metabolism | 2 | 66.0 |
Base Sequence | 20 | 0.0 |
Molecular Sequence Data | 21 | 0.0 |
Endoplasmic Reticulum/metabolism | 8 | 3.0 |
Kinetics | 9 | 0.0 |
Lipoproteins, LDL/metabolism | 3 | 1.0 |
Apolipoproteins B/*secretion | 8 | 32.0 |
Time Factors | 5 | 0.0 |
Cholesterol/blood | 7 | 0.0 |
Lipids/*blood | 2 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
Apolipoproteins B/biosynthesis/genetics/*metabolism | 2 | 100.0 |
Carrier Proteins/metabolism | 5 | 0.0 |
Cysteine Endopeptidases/metabolism | 2 | 0.0 |
Lipoproteins, VLDL/metabolism | 3 | 2.0 |
Multienzyme Complexes/metabolism | 2 | 1.0 |
Proteasome Endopeptidase Complex | 4 | 0.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Hamsters | 6 | 0.0 |
Microsomes, Liver/*metabolism | 2 | 1.0 |
Precipitin Tests | 2 | 0.0 |
Protein Binding | 7 | 0.0 |
Protein Structure, Secondary | 3 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Carrier Proteins/genetics/*metabolism | 6 | 1.0 |
Receptors, LDL/metabolism | 3 | 3.0 |
Carrier Proteins/chemistry/genetics/*physiology | 3 | 8.0 |
Blotting, Western | 4 | 0.0 |
In Vitro | 5 | 0.0 |
Lipids/metabolism | 10 | 3.0 |
Lipoproteins/metabolism | 3 | 2.0 |
Organ Culture Techniques | 2 | 0.0 |
Pregnancy | 2 | 0.0 |
Mice, Knockout | 7 | 0.0 |
Amino Acid Sequence | 13 | 0.0 |
Models, Biological | 5 | 0.0 |
Phylogeny | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Polymerase Chain Reaction | 7 | 0.0 |
*Promoter Regions (Genetics) | 5 | 0.0 |
Abetalipoproteinemia/*genetics | 5 | 71.0 |
Adolescent | 5 | 0.0 |
Carrier Proteins/*genetics/physiology | 2 | 5.0 |
Gene Expression | 6 | 0.0 |
Infant | 3 | 0.0 |
*Mutation | 4 | 0.0 |
RNA Splicing | 3 | 0.0 |
Abetalipoproteinemia/blood/*genetics/therapy | 2 | 100.0 |
Apolipoproteins B/deficiency | 3 | 75.0 |
Vitamin E/therapeutic use | 2 | 13.0 |
Gene Expression Regulation | 4 | 0.0 |
Intestine, Small/metabolism | 2 | 3.0 |
Child | 2 | 0.0 |
Child, Preschool | 2 | 0.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
English Abstract | 2 | 0.0 |
Intestines/ultrastructure | 2 | 100.0 |
Cell Line, Tumor | 3 | 0.0 |
Molecular Weight | 2 | 0.0 |
Mutagenesis | 4 | 0.0 |
Oleic Acid/metabolism/pharmacology | 2 | 66.0 |
Abetalipoproteinemia/genetics | 2 | 100.0 |
Indoles/pharmacology | 3 | 1.0 |
Piperidines/pharmacology | 3 | 5.0 |
Apolipoproteins/blood | 2 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Apolipoproteins B/blood/*secretion | 2 | 66.0 |
Age of Onset | 2 | 0.0 |
Canada | 3 | 2.0 |
Chromosomes, Human, Pair 4 | 2 | 1.0 |
Mutation | 4 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Prospective Studies | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Carrier Proteins/*physiology | 2 | 0.0 |
Microsomes | 2 | 14.0 |
Microsomes, Liver/chemistry | 2 | 50.0 |
Triglycerides/secretion | 3 | 27.0 |
Genetic Screening | 2 | 0.0 |
Haplotypes/genetics | 2 | 0.0 |
Biopsy | 4 | 0.0 |
Chylomicrons/metabolism | 2 | 8.0 |
Intestines/metabolism/pathology | 2 | 40.0 |
Pedigree | 5 | 0.0 |
Carrier Proteins/chemistry/genetics/*metabolism | 3 | 2.0 |
Golgi Apparatus/metabolism | 3 | 1.0 |
*Membrane Transport Proteins | 3 | 0.0 |
Recombinant Proteins/metabolism | 4 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Carrier Proteins/antagonists & inhibitors/*metabolism | 3 | 25.0 |
Recombinant Proteins/biosynthesis | 3 | 0.0 |
Triglycerides/*metabolism | 10 | 11.0 |
Lipoproteins, VLDL/*biosynthesis/*secretion | 2 | 66.0 |
*CCAAT-Enhancer-Binding Proteins | 2 | 1.0 |
Insulin/pharmacology | 2 | 0.0 |
RNA, Messenger/metabolism | 4 | 0.0 |
Receptors, LDL/genetics | 2 | 2.0 |
Transcription Factors/genetics/metabolism | 2 | 0.0 |
Apolipoproteins B/*chemistry/*metabolism | 2 | 50.0 |
Lipoproteins/chemistry/*metabolism | 2 | 15.0 |
Models, Molecular | 2 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Apolipoproteins/*genetics | 2 | 2.0 |
Apolipoproteins B/*genetics | 3 | 1.0 |
Carrier Proteins/chemistry/*genetics | 2 | 3.0 |
Conserved Sequence | 2 | 0.0 |
Exons | 4 | 0.0 |
Oleic Acids/pharmacology | 2 | 9.0 |
Cells, Cultured | 10 | 0.0 |
Lipoproteins, VLDL/blood | 2 | 0.0 |
Transgenes | 2 | 0.0 |
Acyltransferases/*metabolism | 2 | 16.0 |
Oleic Acid/pharmacology | 3 | 9.0 |
Cloning, Molecular | 5 | 0.0 |
DNA Primers | 3 | 0.0 |
Dimerization | 2 | 0.0 |
Spodoptera | 4 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Protein Conformation | 3 | 0.0 |
Binding Sites | 5 | 0.0 |
Drosophila melanogaster | 3 | 2.0 |
Xenopus laevis | 2 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Intestines/metabolism | 4 | 3.0 |
Lipoproteins, VLDL/*metabolism | 2 | 2.0 |
Apolipoproteins B/*biosynthesis | 3 | 20.0 |
Syndrome | 2 | 0.0 |
Endoplasmic Reticulum/*metabolism | 2 | 1.0 |
Cattle | 7 | 0.0 |
Lipoproteins/*secretion | 2 | 25.0 |
Apolipoproteins B/biosynthesis | 2 | 22.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
RNA, Messenger/biosynthesis | 5 | 0.0 |
Transcription, Genetic/*drug effects | 2 | 0.0 |
Case-Control Studies | 4 | 0.0 |
Double-Blind Method | 3 | 0.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use | 2 | 6.0 |
Microsomes/*chemistry | 2 | 100.0 |
Oleic Acid/metabolism | 2 | 9.0 |
DNA/analysis | 2 | 0.0 |
Fatal Outcome | 2 | 0.0 |
Macromolecular Substances | 4 | 0.0 |
Sequence Deletion | 3 | 0.0 |
Carrier Proteins/chemistry/*metabolism | 3 | 3.0 |
Lipoproteins, HDL/metabolism | 2 | 1.0 |
*Triglycerides | 4 | 100.0 |
DNA, Complementary | 4 | 0.0 |
Isomerases/*metabolism | 2 | 20.0 |
Protein Disulfide-Isomerase | 4 | 21.0 |
Tritium | 3 | 1.0 |
Apolipoproteins B/*metabolism/secretion | 2 | 33.0 |
Molecular Structure | 2 | 0.0 |
Oleic Acid | 4 | 6.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Carrier Proteins/biosynthesis/chemistry/*metabolism | 2 | 11.0 |
Cercopithecus aethiops | 2 | 0.0 |
Oleic Acids/metabolism | 3 | 14.0 |
Apolipoproteins B/genetics | 2 | 5.0 |
Apolipoproteins E/metabolism | 2 | 3.0 |
Subcellular Fractions | 2 | 1.0 |
Nucleopolyhedrovirus/genetics | 2 | 9.0 |
Structure-Activity Relationship | 5 | 0.0 |
DNA | 2 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Fibroblasts | 2 | 0.0 |
Body Weight | 2 | 0.0 |
Injections, Intravenous | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Anticholesteremic Agents/*therapeutic use | 2 | 3.0 |
Infant, Newborn | 2 | 0.0 |
Carrier Proteins/*antagonists & inhibitors/metabolism | 2 | 20.0 |
Hypercholesterolemia/*drug therapy | 2 | 18.0 |
*Neoplasm Proteins | 2 | 0.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
Administration, Oral | 2 | 0.0 |
